Oxford Biomedica is leading on a Biotechnology and Biological Sciences Research Council (BBSRC) funded Collaborative Training Partnership (CTP) doctoral training programme called Advanced Bioscience of Viral Products (ABViP), together with our academic partners at the University of Oxford (UOXF) and University College London (UCL). 

ABViP is a comprehensive, multidisciplinary degree programme designed and led by industry. It aims to deliver the next generation of bioscience leaders who will advance research of viral products for future gene therapies and vaccines. The ABViP-CTP will train a cohort of 24 PhD/DPhil students (18 x CTP-funded, 6 x partner-funded), over a seven-year time frame commencing in 2022 to address the acute viral vector skills shortage. We are aiming to initiate approximately 8x doctoral student projects in each of years 2022, 2023 and 2024.

Our partners bring complementary expertise in lentiviral (LV) and adeno-associated viral (AAV) vector bioprocessing, novel analytics and data science methodologies and viral vaccine design, development, and characterisation. The academic institutions have extensive experience in leading high-quality, international doctoral training programmes including UCL’s BBSRC London Interdisciplinary Doctoral Programme DTP (LIDo) and EPSRC CDT in Bioprocess Engineering Leadership and UOXF’s BBSRC Interdisciplinary Bioscience DTP, MRC Interdisciplinary Medical Research DTP, and IBM/EPSRC Computational Discovery programme.

The first cohort of supervisory projects have now been chosen by the ABViP Management Board and the selected students are due to start their doctoral training programme in October 2022. We are now seeking applications for projects for the cohort starting in 2023.

We are now accepting applications for projects from academic supervisors / principal investigators working in relevant fields that align with the ABViP-CTP research themes. Applicants must hold a position at one of our academic partners (UCL or UOXF) for the duration of the doctoral training programme.

A total of nine projects will be selected, four at UCL and five at UOXF to start in October 2023.

To request the application form and guidance notes please email: abvip@oxb.com

Opening date to apply: Monday 8th August 2022

Deadline for applications: Friday 16th September 2022, 12noon.

The ABViP Management board will review all applications and select those that best align with the overarching research aims of the CTP.

For further information please email: abvip@oxb.com

At Oxford Biomedica we recognise the importance of investing in early talent, and we are passionate about supporting the scientific leaders of the future within cell and gene therapy especially as the industry continues to grow.

The intention of the CTP is to attract the very best people to the available PhD / DPhil programmes. Students trained through the ABViP-CTP will gain a holistic insight into the research and development activities required to create the medicines of the future from both an academic and industrial perspective.